Zobrazeno 1 - 10
of 203
pro vyhledávání: '"Roberto Ravasio"'
Publikováno v:
AboutOpen, Vol 11, Iss 1 (2024)
Background: The availability of high-efficacy disease-modifying therapy (DMT), including natalizumab, improved treatment efficacy in adults with highly-active relapsing-remitting multiple sclerosis (RRMS). Natalizumab patent protection has expired, a
Externí odkaz:
https://doaj.org/article/8ab74f99bf844d3593f954dfa63f83ef
Autor:
Rani Pallavi, Elena Gatti, Tiphanie Durfort, Massimo Stendardo, Roberto Ravasio, Tommaso Leonardi, Paolo Falvo, Bruno Achutti Duso, Simona Punzi, Aobuli Xieraili, Andrea Polazzi, Doriana Verrelli, Deborah Trastulli, Simona Ronzoni, Simone Frascolla, Giulia Perticari, Mohamed Elgendy, Mario Varasi, Emanuela Colombo, Marco Giorgio, Luisa Lanfrancone, Saverio Minucci, Luca Mazzarella, Pier Giuseppe Pelicci
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-18 (2024)
Abstract Caloric Restriction (CR) has established anti-cancer effects, but its clinical relevance and molecular mechanism remain largely undefined. Here, we investigate CR’s impact on several mouse models of Acute Myeloid Leukemias, including Acute
Externí odkaz:
https://doaj.org/article/8f7683b064194aa894f4ffe6b6a13e8b
Publikováno v:
Global & Regional Health Technology Assessment, Vol 11, Iss 1 (2024)
Background: Only limited information is available on cost efficacy of the advanced therapies for the treatment of ulcerative rectocolitis. We evaluated the efficacy and the treatment costs of these advanced therapies in the treatment of bio-exposed (
Externí odkaz:
https://doaj.org/article/136e9b6940a54feaa2628dafd71087ae
Autor:
Patrizio Armeni, Elena Compagnucci, Gionata Fiorino, Vincenzo Lolli, Grazia Mazzone, Ambrogio Orlando, Mariabeatrice Principi, Roberto Ravasio, Fernando Rizzello, Edoardo Vincenzo Savarino, Francesca Tombari
Publikováno v:
AboutOpen, Vol 11, Iss 1 (2024)
Background: Vedolizumab (VDZ) and infliximab are used to treat moderate to severe ulcerative colitis (UC). The choice of the drug to use at first-line is often based on a combination of clinical and economic factors. The cost of treatment pathway is
Externí odkaz:
https://doaj.org/article/90574fcbd1c14d66a5e716c5e3dd6224
Publikováno v:
Global & Regional Health Technology Assessment, Vol 11, Iss 1 (2024)
Background: Targeted systemic therapies, including abrocitinib, baricitinib, dupilumab, tralokinumab and upadacitinib, are new treatments for moderate to severe atopic dermatitis (AD). We evaluated the efficacy and the costs of these targeted systemi
Externí odkaz:
https://doaj.org/article/7c5dceb35558477cba60b80d5222de56
Autor:
Roberto Ravasio, Silvia Ripoli
Publikováno v:
AboutOpen, Vol 10, Iss 1 (2023)
Background: Primary (PID) or secondary (SID) immunodeficiencies are diseases caused by quantitative and/or functional alterations of the different mechanisms involved in the innate and adaptive immune response. This economic evaluation was conducted
Externí odkaz:
https://doaj.org/article/3ba17007ad4b4ff793f2f736c0656323
Publikováno v:
AboutOpen, Vol 10, Iss 1 (2023)
Background: The aim of this economic evaluation was to compare the cost per responder between vedolizumab and ustekinumab in patients with Crohn’s disease (CD) after failure of tumor necrosis factor-α inhibitors in Italy. Methods: Clinical effica
Externí odkaz:
https://doaj.org/article/00f6771f147c4d7783b41dd30ef415f4
Autor:
Gian Domenico Sebastiani, Marta Mosca, Roberto Ravasio, Pietro Brambilla, Paola Raimondo, Andrea Doria
Publikováno v:
Global & Regional Health Technology Assessment, Vol 9, Iss 1 (2022)
Background: Systemic lupus erythematosus (SLE) is associated with clinical burden for the patient and organ damage. The development of therapies for SLE has been constrained by clinical and biologic heterogeneity. These represent challenges in clinic
Externí odkaz:
https://doaj.org/article/7b1d28b061ba4ed5a7e93ece221621ea
Publikováno v:
AboutOpen, Vol 9, Iss 1 (2022)
Objective: The aim of this economic evaluation was to assess the cost-utility of brigatinib versus alectinib in the treatment of naïve patients to anaplastic lymphoma kinase-positive advanced non-small cell lung cancer (ALK-positive aNSCLC) from the
Externí odkaz:
https://doaj.org/article/e5e8473143494361a5b3558c56663403
Publikováno v:
Global & Regional Health Technology Assessment, Vol 9, Iss 1 (2022)
Background. Several health care services are required to get eligibility to PCSK9-inhibitors medicines and the follow-up of patients being treated. The ultimate goal is making prescriptions appropriate and monitoring the effects of these drugs. Some
Externí odkaz:
https://doaj.org/article/138fe890f28a4768a3bd0b670edde512